Genoa Pharmaceuticals and McMaster University to collaborate on Idiopathic Pulmonary Fibrosis Research
SAN DIEGO, Jan. 16, 2013 /PRNewswire/ -- Genoa Pharmaceuticals, a leader in the field of pulmonary fibrosis, today announced it is collaborating with Dr. Martin Kolb and researchers at McMaster University to characterize the in vivo advantages and potential clinical impact of Genoa's lead program, inhaled GP-101 (aerosol pirfenidone) for the treatment of IPF. The research will combine Genoa's expertise in aerosol drug delivery with McMaster's expertise in exploring mechanisms of pulmonary fibrosis and managing patients with IPF.
"Genoa is very excited about the opportunity to collaborate with Dr. Kolb and McMaster University to better understand how inhaled GP-101 may benefit IPF patients," said Mark Surber, Ph.D., Genoa's Founder, President and Chief Scientific Officer. "Genoa is committed to establishing academic relationships with leading institutions to further advance its efforts to develop novel treatments for IPF."
"We are very interested to evaluate novel therapies such as GP-101 to better understand the molecular effects and in vivo relationship to the human disease," said Dr. Martin Kolb, M.D., Ph.D. & Associate Professor in the Division of Respirology, within the Department of Medicine Pathology & Molecular Medicine at McMaster University. "We are pleased to collaborate with Genoa as we believe GP-101 has the potential to be a key treatment for IPF."
About Genoa Pharmaceuticals
Related PRNewswire Releases News